MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
Nurix Therapeutics, Inc. (NASDAQ: NRIX)*
Organization & Developments: Nurix
Parents
Nurix Therapeutics, Inc. (NASDAQ: NRIX)*
Children
*Clinical stage biotech company that develops targeted protein modulation drugs
2024: Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
2024: Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
2024: Nurix Therapeutics Receives U.S. FDA Fast Track Designation
2024: Nurix Therapeutics: A Unique Approach To BTK Targeting_ seekingalpha.com
2024: Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
2024: Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now_ seekingalpha.com
2024: Nurix Therapeutics' SWOT analysis: btk degrader stock shows promise amid challenges
2025: Nurix Therapeutics: A Story To Monitor
2025: Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
2025: Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me
Jumps
Finance & Acquisitions: Nurix
Key People: Nurix Therapeutics